Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1981 1
1984 1
1989 2
2003 1
2006 1
2007 1
2008 3
2010 2
2011 4
2012 2
2013 3
2015 1
2016 2
2017 5
2018 4
2019 10
2020 5
2021 10
2022 13
2023 11
2024 5

Text availability

Article attribute

Article type

Publication date

Search Results

79 results

Results by year

Filters applied: . Clear all
Page 1
Exploring the Role of Immunotherapy-Based Treatments for Advanced Non-Small-Cell Lung Cancer With Novel Driver Alterations.
Brambilla M, Beninato T, Piemontese A, Mazzeo L, Pircher CC, Manglaviti S, Ambrosini P, Signorelli D, Lorenzini D, Prelaj A, Ferrara R, Proto C, Lo Russo G, Pizzutilo EG, Ganzinelli M, Grande I, Capone I, Di Mauro RM, Conca E, Dumitrascu AD, Zanella C, Leporati R, Rota S, Garassino MC, Marchetti P, de Braud FM, Occhipinti M. Brambilla M, et al. Among authors: occhipinti m. Clin Lung Cancer. 2023 Nov;24(7):631-640.e2. doi: 10.1016/j.cllc.2023.08.004. Epub 2023 Aug 23. Clin Lung Cancer. 2023. PMID: 37775370 Free article.
Survivals were estimated through Kaplan-Meier method and compared by log-rank test. RESULTS: m-cohort and wt-cohort included 84 and 444 patients, respectively. Progression free survival (PFS) was 5.53 vs. 4.57 months (P= .846) and overall survival (OS) was 25.1 vs. 9.37 mo …
Survivals were estimated through Kaplan-Meier method and compared by log-rank test. RESULTS: m-cohort and wt-cohort included 84 and 4 …
The 5-Ws of immunotherapy in head and neck cancer.
Botticelli A, Mezi S, Pomati G, Cerbelli B, Di Rocco C, Amirhassankhani S, Sirgiovanni G, Occhipinti M, Napoli V, Emiliani A, Mazzuca F, Tomao S, Nuti M, Marchetti P. Botticelli A, et al. Among authors: occhipinti m. Crit Rev Oncol Hematol. 2020 Sep;153:103041. doi: 10.1016/j.critrevonc.2020.103041. Epub 2020 Jun 30. Crit Rev Oncol Hematol. 2020. PMID: 32629362 Review.
The immune checkpoint inhibitors, a class of drugs able to block immune suppressive pathways in order to prime an anticancer immunity, revolutionized standard of care in platinum-refractory recurrent and/or metastatic head and neck carcinoma (R/M HNSCC). The PD-1/ PD-L1 ax …
The immune checkpoint inhibitors, a class of drugs able to block immune suppressive pathways in order to prime an anticancer immunity, revol …
Caloric restriction and metformin selectively improved LKB1-mutated NSCLC tumor response to chemo- and chemo-immunotherapy.
Ndembe G, Intini I, Moro M, Grasselli C, Panfili A, Panini N, Bleve A, Occhipinti M, Borzi C, Garassino MC, Marabese M, Canesi S, Scanziani E, Sozzi G, Broggini M, Ganzinelli M. Ndembe G, et al. Among authors: occhipinti m. J Exp Clin Cancer Res. 2024 Jan 2;43(1):6. doi: 10.1186/s13046-023-02933-5. J Exp Clin Cancer Res. 2024. PMID: 38163906 Free PMC article.
High bone tumor burden to identify advanced non-small cell lung cancer patients with survival benefit upon bone targeted agents and immune checkpoint inhibitors.
Manglaviti S, Bini M, Apollonio G, Zecca E, Galli G, Sangaletti S, Labianca A, Sottotetti E, Brambilla M, Occhipinti M, Proto C, Prelaj A, Signorelli D, De Toma A, Viscardi G, Beninato T, Mazzeo L, Bottiglieri A, Leporati R, Fotia G, Ganzinelli M, Portararo P, Garassino MC, de Braud FGM, Lo Russo G, Torri V, Ferrara R. Manglaviti S, et al. Among authors: occhipinti m. Lung Cancer. 2023 Dec;186:107417. doi: 10.1016/j.lungcan.2023.107417. Epub 2023 Oct 29. Lung Cancer. 2023. PMID: 37918061
RESULTS: Of 134 patients included, 51 (38 %) received BTA. At a mFU of 39.6 months (m), BTA-ICIs concurrent treatment did not significantly impact on mOS [8.3 m (95% CI 3.9-12.8) versus (vs) 6.8 m (95% CI 4.0-9.6) p = 0.36]; these results were confirmed after …
RESULTS: Of 134 patients included, 51 (38 %) received BTA. At a mFU of 39.6 months (m), BTA-ICIs concurrent treatment did not signifi …
A novel 3'-tRNAGlu-derived fragment acts as a tumor suppressor in breast cancer by targeting nucleolin.
Falconi M, Giangrossi M, Zabaleta ME, Wang J, Gambini V, Tilio M, Bencardino D, Occhipinti S, Belletti B, Laudadio E, Galeazzi R, Marchini C, Amici A. Falconi M, et al. Among authors: occhipinti s. FASEB J. 2019 Dec;33(12):13228-13240. doi: 10.1096/fj.201900382RR. Epub 2019 Sep 27. FASEB J. 2019. PMID: 31560576
Here, we provide evidence that tRF3E plays an important role in the pathogenesis of BC displaying tumor-suppressor functions through a NCL-mediated mechanism.-Falconi, M., Giangrossi, M., Elexpuru Zabaleta, M., Wang, J., Gambini, V., Tilio, M., Bencard …
Here, we provide evidence that tRF3E plays an important role in the pathogenesis of BC displaying tumor-suppressor functions through a NCL-m …
Immune-Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer With Uncommon Histology.
Manglaviti S, Brambilla M, Signorelli D, Ferrara R, Lo Russo G, Proto C, Galli G, De Toma A, Occhipinti M, Viscardi G, Beninato T, Zattarin E, Bini M, Lobefaro R, Massa G, Bottiglieri A, Apollonio G, Sottotetti E, Di Mauro RM, Trevisan B, Ganzinelli M, Fabbri A, de Braud FGM, Garassino MC, Prelaj A. Manglaviti S, et al. Among authors: occhipinti m. Clin Lung Cancer. 2022 Jan;23(1):e17-e28. doi: 10.1016/j.cllc.2021.06.013. Epub 2021 Jul 5. Clin Lung Cancer. 2022. PMID: 34334296
In UH group, programmed death-ligand 1 (PD-L1) <1%, 1-49%, 50% and unknown expression were reported in 27.8%, 22.8%, 31.7% and 17.7% patients respectively and ICI was the second/further-line in the majority of patients. After a median follow-up of 35.64 months (m), medi …
In UH group, programmed death-ligand 1 (PD-L1) <1%, 1-49%, 50% and unknown expression were reported in 27.8%, 22.8%, 31.7% and 17.7% pati …
Measuring Masculinity in Men With Chronic Disease.
Occhipinti S, Laurie K, Hyde MK, Martin S, Oliffe J, Wittert G, Chambers SK. Occhipinti S, et al. Am J Mens Health. 2019 Jul-Aug;13(4):1557988319859706. doi: 10.1177/1557988319859706. Am J Mens Health. 2019. PMID: 31268378 Free PMC article.
The present study assessed the validity of the MCD-I in men with other chronic diseases to explore its potential for wider application. A cross-sectional survey of 633 men aged 47-93 years old (M = 68 years), of whom 68% reported 2 chronic conditions, was conducted. ...
The present study assessed the validity of the MCD-I in men with other chronic diseases to explore its potential for wider application. A cr …
79 results